Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06518070
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-06-01
Brief Title:
Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Results Comparison of Cervical Cancer Early Detection Using Cerviray With VIA Test
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cervical cancer primarily caused by Human Papilloma Virus HPV is a significant global health concern ranking as the fourth most common cancer in women worldwide In Indonesia it stands as the second most frequent cancer among women This study investigates the performance of Cerviray AI and Cerviray AI Evaluation an artificial intelligence AI technology for diagnosing cervical cancer aiming to compare its sensitivity specificity positive predictive value PPV and area under the receiver operating characteristic curve AUC ROC with the Visual Inspection with Acetic Acid VIA test
Detailed Description:
The study involved 44 patients from various health centers in West Java Province Cerviray AI Cerviray AI Evaluation and VIA tests were administered to high-risk women of childbearing age
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None